Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us
Already have a subscription?Sign In

Access All Charts and Data

Transparently sourced data in visual form, perfect for legitimizing your strategic ideas and thought leadership via internal and external presentations.

Access All Charts and Data

Transparently sourced data in visual form, perfect for legitimizing your strategic ideas and thought leadership via internal and external presentations.

Get a Demo
February 14, 2022

Willingness to Prescribe Prescription Digital Therapeutics (PDTs) According to US Physicians, Oct 2021 (% of respondents)

Note

Data was provided to Insider Intelligence by Cowen & Company.

Methodology

Data is from the February 2022 Cowen & Company "Physician Survey on Prescription Digital Therapeutics." 200 US physicians were surveyed during September-October, 2021, spanning across four indications: type 2 diabetes, pediatric attention-deficit/hyperactivity disorder (ADHD), substance use and opioid disorder, and chronic insomnia. The five products around which the survey centered are BT-001 (Better Therapeutics), EndeavorRx (Akili Interactive), reSET and reSET-O (Pear Therapeutics), and Somryst (Pear Therapeutics). This list is not exhaustive of all PDTs, either approved or in development. Cowen & Company, LLC and/or its affiliates make a market in the stock of Better Therapeutics and Pear Therapeutics securities.